{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:21:41Z","timestamp":1786548101573,"version":"build-2736575974"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/ajg.2016.105","type":"journal-article","created":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T11:11:19Z","timestamp":1459249879000},"page":"779-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current Status of Celiac Disease Drug Development"],"prefix":"10.14309","volume":"111","author":[{"given":"Manida","family":"Wungjiranirun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran P","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A","family":"Leffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210210","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/gutjnl-2013-306578","article-title":"Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology.","volume":"63","author":"Ludvigsson","year":"2014","journal-title":"Gut"},{"key":"R2-17-20210210","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ajpath.2011.10.019","article-title":"Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease.","volume":"180","author":"Menard","year":"2012","journal-title":"Am J Pathol"},{"key":"R3-17-20210210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev-immunol-040210-092915","article-title":"Integration of genetic and immunological insights into a model of celiac disease pathogenesis.","volume":"29","author":"Abadie","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"R4-17-20210210","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s10620-014-3143-1","article-title":"Clinical utility of celiac disease-associated HLA testing.","volume":"59","author":"Pallav","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R5-17-20210210","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4049\/jimmunol.175.1.254","article-title":"Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation.","volume":"175","author":"Qiao","year":"2005","journal-title":"J Immunol"},{"key":"R6-17-20210210","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.coi.2011.08.006","article-title":"Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders.","volume":"23","author":"Sollid","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"R7-17-20210210","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jaad.2010.09.777","article-title":"Dermatitis herpetiformis. Part I. epidemiology, pathogenesis, and clinical presentation.","volume":"64","author":"Bolotin","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R8-17-20210210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ana.21450","article-title":"Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.","volume":"64","author":"Hadjivassiliou","year":"2008","journal-title":"Ann Neurol"},{"key":"R9-17-20210210","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1056\/NEJMe030050","article-title":"Celiac disease-how to handle a clinical chameleon.","volume":"348","author":"Fasano","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-17-20210210","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/ajg.2012.219","article-title":"The prevalence of celiac disease in the United States.","volume":"107","author":"Rubio-Tapia","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R11-17-20210210","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bmj.38169.486701.7C","article-title":"Malignancy and mortality in people with coeliac disease: population based cohort study.","volume":"329","author":"West","year":"2004","journal-title":"BMJ"},{"key":"R12-17-20210210","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jama.2009.1320","article-title":"Small-intestinal histopathology and mortality risk in celiac disease.","volume":"302","author":"Ludvigsson","year":"2009","journal-title":"JAMA"},{"key":"R13-17-20210210","first-page":"47154","article-title":"Food labeling: gluten-free labeling of foods. Final rule.","volume":"78","author":"Food and Drug Administration","year":"2013","journal-title":"Fed Regist"},{"key":"R14-17-20210210","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jada.2010.03.014","article-title":"Gluten contamination of grains, seeds, and flours in the United States: a pilot study.","volume":"110","author":"Thompson","year":"2010","journal-title":"J Am Diet Assoc"},{"key":"R15-17-20210210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.appet.2013.04.016","article-title":"Intentional and inadvertent non-adherence in adult coeliac disease. A cross-sectional survey.","volume":"68","author":"Hall","year":"2013","journal-title":"Appetite"},{"key":"R16-17-20210210","first-page":"391","article-title":"Factors influencing the type, timing and severity of symptomatic responses to dietary gluten in patients with biopsy-proven coeliac disease.","volume":"22","author":"Barratt","year":"2013","journal-title":"J Gastrointestin Liver Dis"},{"key":"R17-17-20210210","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","article-title":"A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease.","volume":"85","author":"Catassi","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"R18-17-20210210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2006.12.006","article-title":"Etiologies and predictors of diagnosis in nonresponsive celiac disease.","volume":"5","author":"Leffler","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R19-17-20210210","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/apt.12621","article-title":"Predictors of persistent villous atrophy in coeliac disease: a population-based study.","volume":"39","author":"Lebwohl","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-17-20210210","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ajg.2010.10","article-title":"Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet.","volume":"105","author":"Rubio-Tapia","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R21-17-20210210","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2036.2009.03992.x","article-title":"Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet.","volume":"29","author":"Lanzini","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R22-17-20210210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-277X.2007.00763.x","article-title":"Economic burden of a gluten-free diet.","volume":"20","author":"Lee","year":"2007","journal-title":"J Hum Nutr Diet"},{"key":"R23-17-20210210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-277X.2005.00607.x","article-title":"Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods?","volume":"18","author":"Thompson","year":"2005","journal-title":"J Hum Nutr Diet"},{"key":"R24-17-20210210","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2036.2012.05001.x","article-title":"Body mass index and the risk of obesity in coeliac disease treated with the gluten-free diet.","volume":"35","author":"Kabbani","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-17-20210210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/17474124.2014.876360","article-title":"Nutritional consequences of celiac disease and the gluten-free diet.","volume":"8","author":"Theethira","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R26-17-20210210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-277X.2005.00591.x","article-title":"Controlled by food- lived experiences of coeliac disease.","volume":"18","author":"Sverker","year":"2005","journal-title":"J Hum Nutr Diet"},{"key":"R27-17-20210210","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ajg.2014.29","article-title":"Patient perception of treatment burden is high in celiac disease compared with other common conditions.","volume":"109","author":"Shah","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R28-17-20210210","first-page":"27","article-title":"Are patients with coeliac disease seeking alternative therapies to a gluten-free diet?","volume":"20","author":"Aziz","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"key":"R29-17-20210210","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1756283X13492580","article-title":"Interest in medical therapy for celiac disease.","volume":"6","author":"Tennyson","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"R30-17-20210210","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1053\/j.gastro.2009.09.008","article-title":"Celiac disease: from pathogenesis to novel therapies.","volume":"137","author":"Schuppan","year":"2009","journal-title":"Gastroenterology"},{"key":"R31-17-20210210","first-page":"582","article-title":"Emerging therapeutic options for celiac disease: potential alternatives to a gluten-free diet.","volume":"8","author":"Bakshi","year":"2012","journal-title":"Gastroenterol Hepatol"},{"key":"R32-17-20210210","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/gut.2005.068684","article-title":"Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease.","volume":"55","author":"Di Sabatino","year":"2006","journal-title":"Gut"},{"key":"R33-17-20210210","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1053\/j.gastro.2006.12.025","article-title":"Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease.","volume":"132","author":"Benahmed","year":"2007","journal-title":"Gastroenterology"},{"key":"R34-17-20210210","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2249.2008.03743.x","article-title":"Higher constitutive IL15R alpha expression and lower IL-15 response threshold in coeliac disease patients.","volume":"154","author":"Bernardo","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"R35-17-20210210","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/gast.2000.18149","article-title":"Interleukin 15 mediates epithelial changes in celiac disease.","volume":"119","author":"Maiuri","year":"2000","journal-title":"Gastroenterology"},{"key":"R36-17-20210210","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0016-5085(03)01047-3","article-title":"Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease.","volume":"125","author":"Mention","year":"2003","journal-title":"Gastroenterology"},{"key":"R37-17-20210210","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.21249","article-title":"Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.","volume":"52","author":"Baslund","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R38-17-20210210","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2006.08.031","article-title":"Antibody blockade of CCL25CCR9 ameliorates early but not late chronic murine ileitis.","volume":"131","author":"Rivera-Nieves","year":"2006","journal-title":"Gastroenterology"},{"key":"R39-17-20210210","first-page":"58942","article-title":"New drug, antibiotic, and biological drug product regulations; accelerated approval-FDA. Final rule.","volume":"57","year":"1992","journal-title":"Fed Regist"},{"key":"R40-17-20210210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/apt.12164","article-title":"Mucosal healing and mortality in coeliac disease.","volume":"37","author":"Lebwohl","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R41-17-20210210","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1007\/s10620-010-1342-y","article-title":"Psychosocial factors are more important than disease activity in determining gastrointestinal symptoms and health status in adults at a celiac disease referral center.","volume":"55","author":"Dorn","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R42-17-20210210","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinternmed.2010.373","article-title":"The incidence and cost of unexpected hospital use after scheduled outpatient endoscopy.","volume":"170","author":"Leffler","year":"2010","journal-title":"Arch Intern Med"},{"key":"R43-17-20210210","first-page":"774","article-title":"Optimal approach to obtaining mucosal biopsies for assessment of inflammatory disorders of the gastrointestinal tract.","volume":"104","author":"Yantiss","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R44-17-20210210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ajg.2009.557","article-title":"Variability of histopathological changes in childhood celiac disease.","volume":"105","author":"Weir","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R45-17-20210210","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MCG.0000000000000105","article-title":"Titers of anti-tissue transglutaminase antibody correlate well with severity of villous abnormalities in celiac disease.","volume":"49","author":"Singh","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"R46-17-20210210","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1572-0241.2000.01838.x","article-title":"Disappearance of endomysial antibodies in treated celiac disease does not indicate histological recovery.","volume":"95","author":"Dickey","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R47-17-20210210","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/j.1572-0241.2001.03947.x","article-title":"Disappointing sensitivity of endoscopic markers for villous atrophy in a high-risk population: implications for celiac disease diagnosis during routine endoscopy.","volume":"96","author":"Dickey","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R48-17-20210210","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/gutjnl-2012-302196","article-title":"Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease.","volume":"62","author":"Leffler","year":"2012","journal-title":"Gut"},{"key":"R49-17-20210210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/erp.11.12","article-title":"Interpreting patient-reported outcome results: US FDA guidance and emerging methods.","volume":"11","author":"McLeod","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R50-17-20210210","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.cgh.2009.07.031","article-title":"A validated disease-specific symptom index for adults with celiac disease.","volume":"7","author":"Leffler","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R51-17-20210210","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease.","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R53-17-20210210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/nmo.12151","article-title":"FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?","volume":"25","author":"Corsetti","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"R56-17-20210210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/08830185.2011.598978","article-title":"Important lessons derived from animal models of celiac disease.","volume":"30","author":"Marietta","year":"2011","journal-title":"Int Rev Immunol"},{"key":"R57-17-20210210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.peptides.2012.02.015","article-title":"Larazotide acetate regulates epithelial tight junctions in vitro and in vivo.","volume":"35","author":"Gopalakrishnan","year":"2012","journal-title":"Peptides"},{"key":"R58-17-20210210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1258\/ebm.2011.011294","article-title":"In vitro models for gluten toxicity: relevance for celiac disease pathogenesis and development of novel treatment options.","volume":"237","author":"Lindfors","year":"2012","journal-title":"Exp Biol Med"},{"key":"R59-17-20210210","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10620-011-1906-5","article-title":"Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.","volume":"57","author":"Siegel","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R60-17-20210210","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1038\/ajg.2010.276","article-title":"Update on serologic testing in celiac disease.","volume":"105","author":"Leffler","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R61-17-20210210","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","article-title":"Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.","volume":"146","author":"Lahdeaho","year":"2014","journal-title":"Gastroenterology"},{"key":"R62-17-20210210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.12147","article-title":"Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.","volume":"37","author":"Kelly","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R63-17-20210210","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/ajg.2012.211","article-title":"A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.","volume":"107","author":"Leffler","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R64-17-20210210","doi-asserted-by":"crossref","first-page":"e24092","DOI":"10.1371\/journal.pone.0024092","article-title":"Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection.","volume":"6","author":"McSorley","year":"2011","journal-title":"PLoS ONE"},{"key":"R65-17-20210210","doi-asserted-by":"crossref","first-page":"e17366","DOI":"10.1371\/journal.pone.0017366","article-title":"Effect of hookworm infection on wheat challenge in celiac diseasea randomised double-blinded placebo controlled trial.","volume":"6","author":"Daveson","year":"2011","journal-title":"PLoS ONE"},{"key":"R67-17-20210210","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3748\/wjg.v19.i35.5837","article-title":"Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study.","volume":"19","author":"Tack","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R68-17-20210210","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0140-6736(94)91837-6","article-title":"Wheat peptide challenge in coeliac disease.","volume":"343","author":"Sturgess","year":"1994","journal-title":"Lancet"},{"key":"R69-17-20210210","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1039\/c3pp50337b","article-title":"Identifiability of models for time-resolved fluorescence with underlying distributions of rate constants.","volume":"13","author":"Boens","year":"2014","journal-title":"Photochem Photobiol Sci"},{"key":"R70-17-20210210","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2015.02.008","article-title":"Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.","volume":"148","author":"Leffler","year":"2015","journal-title":"Gastroenterology"},{"key":"R71-17-20210210","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/MPG.0b013e3182653c85","article-title":"Navigating the gluten-free diet in college.","volume":"55","author":"Panzer","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R72-17-20210210","first-page":"241","article-title":"Quality of life in coeliac disease is determined by perceived degree of difficulty adhering to a gluten-free diet, not the level of dietary adherence ultimately achieved.","volume":"20","author":"Barratt","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"key":"R73-17-20210210","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2036.2007.03413.x","article-title":"The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study.","volume":"26","author":"Paterson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R74-17-20210210","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaci.2014.07.022","article-title":"Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease.","volume":"135","author":"Croese","year":"2015","journal-title":"J Allergy Clin Immunol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2016105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016105","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201606000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:21:48Z","timestamp":1786544508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201606000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2016.105","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}